Comprehensive Analysis Identified Glycosyltransferase Signature to Predict Glioma Prognosis and TAM Phenotype

Figure 5

Clinical relevance of glycosyltransferase signature. (a) K-M curves to assess prognostic differences between the high- and low risk-groups in the aged and nonaged patients belonging to training cohort. (b) K-M curves to evaluate prognostic differences between the high- and low-risk groups of male and female patients belonging to the training cohort. (c) K-M curves to estimate the prognostic differences between the high- and low-risk groups of radiotherapy and nonradiotherapy patients belonging to the training cohort. (d) K-M curves to assess the prognostic differences between the high-risk and low-risk groups of patients without neoadjuvant chemotherapy in training cohort. (e) K-M curves to assess prognostic differences between the high- and low-risk groups in the aged and nonaged patients belonging to validation cohort. (f) K-M curves to evaluate prognostic differences between the high- and low-risk groups of low- and high-grade patients belonging in the validation cohort. (g) K-M curves to estimate the prognostic differences between the high- and low-risk groups of radiotherapy and nonradiotherapy patients belonging to the training cohort. (h) K-M curves to assess the prognostic differences between the high-risk and low-risk groups of patients with or without chemotherapy in training cohort. (i) K-M curves to estimate the prognostic differences between the high- and low-risk groups of PRS type and without PRS type patients in the training cohort. K-M: Kaplan-Meier; PRS: primary recurrent secondary.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)